In the era of comprehensive molecular analyses, the characterization and taxonomy of aggressive B-cell malignancies has greatly evolved. Since the 2017 release of the current version of the World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissue, several whole exome sequencing (WES) as well as whole genome sequencing (WGS) and transcriptome (RNA-seq) studies unraveled novel molecularly defined (sub-) groups, such as the genomic clusters in diffuse large B-cell lymphoma (DLBCL), and their specific therapeutic vulnerabilities. However, the range of aggressive B-cell Non-Hodgkin lymphomas (NHL) still covers a vast spectrum of subtypes, many of which remain insufficiently characterized.
Moreover, the methodical spectrum of genomic analyses is rapidly evolving with single-cell sequencing and other approaches offering new dimensions of insight into lymphoma pathobiology, providing novel information for future treatment strategies in the era of precision oncology and tools for individual risk stratification. Additionally, the spatial order of the lymphoma’s genomic, transcriptional and phenotypic evolution and cell-cell interactions can be dissected on innovative spatial platforms. Further, the study of epigenetics as well as the role of the adaptive immune system as part of the tumor microenvironment pose emerging fields of lymphoma research. Recent developments will thereby help to uncover specific pathomechanisms across lymphoma subtypes, facilitate risk stratification and ultimately pave the way for targeted treatment approaches.
This Research Topic aims to collect translational and clinical research focusing on genomic investigations and novel therapeutic vulnerabilities covering the entire spectrum of aggressive B-cell NHL.
We welcome Original Research, Review Articles and Expert Opinions on topics including, but not limited to:
1. Risk stratification based on molecular features in aggressive B-cell NHL
2. Novel molecular features based on genomic analyses (Targeted Sequencing, WES, WGS, WTS and Methylation profiling) in aggressive B-cell NHL
3. Results from spatial multiomics analysis in aggressive B-cell NHL
4. The investigation of novel therapeutic targets and/or their functional validation in preclinical models
5. Results from investigations of novel therapeutic approaches in preclinical models or early stages of clinical trials
6. Biomarker studies from clinical trials in aggressive B-cell NHL
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
In the era of comprehensive molecular analyses, the characterization and taxonomy of aggressive B-cell malignancies has greatly evolved. Since the 2017 release of the current version of the World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissue, several whole exome sequencing (WES) as well as whole genome sequencing (WGS) and transcriptome (RNA-seq) studies unraveled novel molecularly defined (sub-) groups, such as the genomic clusters in diffuse large B-cell lymphoma (DLBCL), and their specific therapeutic vulnerabilities. However, the range of aggressive B-cell Non-Hodgkin lymphomas (NHL) still covers a vast spectrum of subtypes, many of which remain insufficiently characterized.
Moreover, the methodical spectrum of genomic analyses is rapidly evolving with single-cell sequencing and other approaches offering new dimensions of insight into lymphoma pathobiology, providing novel information for future treatment strategies in the era of precision oncology and tools for individual risk stratification. Additionally, the spatial order of the lymphoma’s genomic, transcriptional and phenotypic evolution and cell-cell interactions can be dissected on innovative spatial platforms. Further, the study of epigenetics as well as the role of the adaptive immune system as part of the tumor microenvironment pose emerging fields of lymphoma research. Recent developments will thereby help to uncover specific pathomechanisms across lymphoma subtypes, facilitate risk stratification and ultimately pave the way for targeted treatment approaches.
This Research Topic aims to collect translational and clinical research focusing on genomic investigations and novel therapeutic vulnerabilities covering the entire spectrum of aggressive B-cell NHL.
We welcome Original Research, Review Articles and Expert Opinions on topics including, but not limited to:
1. Risk stratification based on molecular features in aggressive B-cell NHL
2. Novel molecular features based on genomic analyses (Targeted Sequencing, WES, WGS, WTS and Methylation profiling) in aggressive B-cell NHL
3. Results from spatial multiomics analysis in aggressive B-cell NHL
4. The investigation of novel therapeutic targets and/or their functional validation in preclinical models
5. Results from investigations of novel therapeutic approaches in preclinical models or early stages of clinical trials
6. Biomarker studies from clinical trials in aggressive B-cell NHL
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
